Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics and Neurofit and Beckman Coulter and pION

Premium

Bionomics to Acquire CRO Neurofit for $1.65M; CNS Tx Development Planned

Bionomics will acquire Neurofit, a French contract research organization, in a €1.25 million ($1.65 million) cash-and-stock transaction expected to close before March 1, the Adelaide, Australia-based company said last week.

Bionomics will pay €1 million in cash and €250,000 in shares for Strasbourg, France-based Neurofit. The company conducts preclinical testing of developmental therapeutics for CNS disorders using cellular and animal models, and lists Novartis, Serono, Boehringer-Ingelheim, and Biogen as clients.

The acquisition will enhance Bionomics’ therapeutic development capacity for CNS disorders, Bionomics said.

Additionally, the acquisition includes intellectual property rights to an animal model of Parkinson’s disease, developed by Institute Pasteur, and other animal models.

Earlier this year, Bionomics inked an agreement with PerkinElmer to collaborate on drug screening programs against ion channel and G-protein coupled receptor targets (see Inside Bioassays, 5/18/2004).


Beckman Coulter, Pion Pen Distribution Pact for Drug Permeability-analysis Instruments

Beckman Coulter has entered into a five-year distribution pact with pION to deliver instruments for the automation of in vitro drug-permeability instruments, Beckman Coulter said last week.

The firms will combine Beckman Coulter’s Biomek FX liquid handling system with pION’s double-sink method for parallel artificial membrane permeability analysis. The new instrument, called Biomek FX-ADME/tox Workstation, is controlled by software developed by Woburn, Mass.-based pION.

Beckman has validated the automated system and will distribute it worldwide. The firms will collaborate on application-specific customer support and training.

Financial terms of the deal were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.